Information Library
Enrollment & retention
To learn more about a particular aspect of Quintiles’ pharma services, biotech development or drug commercialization services, select a topic at left. If you’ve already specified a choice, you may narrow your search by selecting additional categories in any order. For example, for information on oncology drug development, start by selecting oncology. Then you can narrow your search to Central Lab, News Releases and Europe.
- Sort by:
- Most Recent
- Title
-
New and Evolving PR and Retention Strategies
July 7, 2010
Jim Kremidas' presentation at DIA US 2010 New and Evolving PR and Retention Strategies -
DIA Recruitment Accountability
July 7, 2010
Jim Kremidas' presentation DIA Recruitment Accountability given at DIA US 2010. -
Breakthrough Motivation
June 24, 2010
Quintiles' Expertise, Network Maximize Recruitment -
Strategic Communication
June 24, 2010
Exceeding Global Recruitment Targets - 6 Months Early -
Extraordinary Results
June 24, 2010
9-Month Savings Nets 50% More Patients -
Accelerated Access
June 2, 2010
Quintiles drew on extensive experience, a thorough understanding of the disease state and a myriad of tools in the Quintiles recruitment arsenal for a comprehensive solution to reach the right patients at the right time. -
QUINTILES AND KAISER PERMANENTE ANNOUNCE ALLIANCE TO ACCELERATE DRUG DEVELOPMENT
May 18, 2010 - Quintiles is accelerating drug development with the addition of Kaiser Permanente's Southern California Permanente Medical Group to its global site program
-
Clinical Trial Educators
May 13, 2010
Because speed and efficiency have never been more critical to the success of your clinical studies, Quintiles now offers a unique resource proven to compress timelines in clinical trials. -
Pioneering Strategy
May 13, 2010
Find out how a pharmaceutical company used the clinical trial educator strategy to accelerate enrollment in a multi-country cardiovascular clinical trial. -
Journal for Clinical Studies
May 12, 2010
In the March 2010 Journal for Clinical Studies, Dr. Erica Caveney and Dr. Rick Turner analyze the EMA Guidance on diabetes drugs and cardiovascular risk.
